# How a Specific Peptide Boosts the Immune System Against Cancer > This patent describes a specific peptide sequence, KESDGFHRF, combined with immune-boosting substances and a safe delivery method, for use in treating cancer through immunotherapy. - **Patent:** US 11542303 - **Original title:** Peptides and combination thereof for use in the immunotherapy against cancers - **Owner:** Immatics Biotechnologies - **Granted:** 2023 - **Status:** Active - **Times cited:** 1 - **Field:** biotech, pharmaceutical, immunotherapy ## What it does This patent claims a specific recipe for a cancer treatment. It involves a particular protein fragment, called a peptide, with the exact amino acid sequence KESDGFHRF (Claim 1). This peptide is combined with an 'adjuvant,' which is a substance that helps make the immune response stronger. The patent lists several possible adjuvants, including imiquimod, GM-CSF, and various interleukins like IL-2, IL-7, IL-12, IL-15, and IL-21 (Claim 2). All these ingredients are mixed into a 'pharmaceutically acceptable carrier,' which is a safe way to deliver the medicine to a patient. For example, a composition could include the KESDGFHRF peptide, IL-2 as the adjuvant (Claim 3), and a buffer for stability (Claim 8), all within a safe liquid carrier for injection. ## What it does NOT cover - Does not cover cancer immunotherapies that use different peptide sequences than KESDGFHRF. - Does not cover the peptide KESDGFHRF when administered without an adjuvant. - Does not cover the peptide KESDGFHRF without a pharmaceutically acceptable carrier. - Does not cover using only the listed adjuvants without the specific KESDGFHRF peptide. - Does not cover non-immunotherapy treatments for cancer, such as chemotherapy alone. ## The clever bit The novelty lies in identifying and claiming a very specific nine-amino-acid peptide, KESDGFHRF, as a key component for stimulating an immune response against tumors. The patent then combines this specific peptide with known immune-boosting adjuvants and delivery methods, creating a precise formulation for immunotherapy. ## Real-world examples 1. Experimental cancer vaccines 2. T-cell stimulating therapies 3. Immunotherapy drug candidates ## Why it matters Cancer immunotherapy aims to train a patient's own immune system to recognize and destroy cancer cells. This patent contributes to that field by identifying a specific peptide that can potentially act as a target for the immune system. By combining this peptide with adjuvants, the goal is to create a stronger, more focused anti-tumor immune response, offering a new approach to fight various cancers. ## Frequently asked questions ### What does How a Specific Peptide Boosts the Immune System Against Cancer cover? This patent describes a specific peptide sequence, KESDGFHRF, combined with immune-boosting substances and a safe delivery method, for use in treating cancer through immunotherapy. ### Who owns patent US 11542303? Immatics Biotechnologies owns this patent, granted in 2023. ### When does this patent expire? This patent is expected to expire on June 25, 2041, when the invention enters the public domain. ### What is patent US 11542303 cited by? This patent has been cited by 1 later patents that build on its ideas. ### What problem does this patent solve? Cancer immunotherapy aims to train a patient's own immune system to recognize and destroy cancer cells. This patent contributes to that field by identifying a specific peptide that can potentially act as a target for the immune system. By combining this peptide with adjuvants, the goal is to create a stronger, more focused anti-tumor immune response, offering a new approach to fight various cancers. ### What does this patent NOT cover? Does not cover cancer immunotherapies that use different peptide sequences than KESDGFHRF. **Full plain-English explainer:** https://patentbrief.org/patent/us/11542303/peptides-and-combination-thereof-for-use-in-the-immunotherapy-against-cancers **Original patent:** https://patents.google.com/patent/US11542303 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [How a Specific Protein Fragment Can Train Immune Cells to Fight Cancer](https://patentbrief.org/patent/us/10314897/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-various-ca) — This patent describes methods to fight various cancers by using a specific protein fragment (peptide LYHDIFSRL) to train a patient's immune cells to recognize and attack tumor cells. - [Treating Liver Cancer with Specially Trained Immune Cells](https://patentbrief.org/patent/us/12168044/peptides-and-combination-of-peptides-for-use-in-immunotherapy-against-non-small-) — This patent describes a method for treating hepatocellular cancer by giving patients specially activated immune cells that are trained to recognize and kill cancer cells displaying a specific protein fragment. - [How an mRNA Vaccine for Lung Cancer Teaches the Immune System to Fight](https://patentbrief.org/patent/us/20160168227/composition-and-vaccine-for-treating-lung-cancer) — This patent describes a specific mRNA vaccine designed to treat lung cancer by instructing the body's cells to produce six distinct tumor proteins, thereby training the immune system to recognize and attack cancer cells. - [How an mRNA Vaccine Targets Prostate Cancer with Six Antigens](https://patentbrief.org/patent/us/20160166668/composition-and-vaccine-for-treating-prostate-cancer) — This patent describes an mRNA vaccine designed to treat prostate cancer by delivering genetic instructions for a specific combination of six prostate-related proteins, teaching the body to fight the cancer. - [How Special Molecules Boost Cancer-Fighting CAR-T Cells](https://patentbrief.org/patent/us/20240082373/compositions-for-chimeric-antigen-receptor-t-cell-therapy-and-uses-thereof) — This patent describes special molecules made of a CAR-T cell activator attached to a fat-like part, designed to make cancer-fighting CAR-T cells grow and work better inside a patient.